Loading clinical trials...
Loading clinical trials...
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Interventions
Phase1 and Phase 2: decitabine
Phase 1: cytarabine
+1 more
Locations
17
Belgium
Ghent, Belgium
Copenhagen Ø, Denmark
Paris, France
Toulouse, France
Vandœuvre-lès-Nancy, France
Essen, Germany
Start Date
October 22, 2013
Primary Completion Date
August 28, 2017
Completion Date
August 28, 2017
Last Updated
June 17, 2019
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions